Bal Pharma Limited

BALPHARMA

INE083D01012

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:51 31/05/2024 BST			5-day change	1st Jan Change
114.6 ^INR	-5.65%		+14.87%	+14.05%

05-28	Bal Pharma Limited Recommends Dividend	CI
05-28	Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Bal Pharma Limited Appoints Akash Mathur as Chief Executive Officer, Effective September 01, 2016

August 29, 2016 at 02:16 pm

Bal Pharma Ltd. announced that the board of directors of the company at its meeting held on August 29, 2016, has appointed Mr. Akash Mathur as the Chief Executive Officer of the company, with effect from September 01, 2016.

Latest news about Bal Pharma Limited

Bal Pharma Limited Recommends Dividend	05-28	CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-28	CI
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Bal Pharma Limited Approves Dividend	25/09/23	CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/08/23	CI
Bal Pharma Limited Appoints Abdul Basith as Company Secretary and Compliance Officer	17/07/23	CI
Bal Pharma Limited Appoints Nicola Neeladri as Additional Director	01/06/23	CI
Bal Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/05/23	CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/05/23	CI
Bal Pharma Limited Recommends Dividend	29/05/23	CI
Bal Pharma Limited Announces Resignation of Mrs.Preeti Singh as Company Secretary	15/05/23	CI
Acuite Keeps BBB- Rating on Bal Pharma's Bank Loans; Outlook Stable	25/04/23	MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	06/02/23	CI
Bal Pharma CFO Resigns	25/11/22	MT
Bal Pharma Limited Announces Resignation of Mr. G. Rengarajan as Chief Financial Officer	24/11/22	CI
Bal Pharma Limited Reports Earnings Results for the Half Year Ended September 30, 2022	14/11/22	CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Bal Pharma Limited Declares Dividend	19/09/22	CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	11/08/22	CI
Bal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent)	30/05/22	CI
Bal Pharma Limited Recommends Dividend	30/05/22	CI
Acuite Upgrades Rating on Bal Pharma's Fund-Based Financing to BBB-; Lowers Outlook to Stable	22/02/22	MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	10/02/22	CI
ICRA Maintains BB+ Rating on Bal Pharma's Long-Term Bank Financing; Raises Outlook to Positive	22/12/21	MT

Chart Bal Pharma Limited

Duration

Period

More charts

Company Profile

Bal Pharma Limited is a fully integrated pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It is specialized in bulk actives, prescription drugs, generics and pharma intermediates. Its focused therapeutic areas are anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. It offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment. Its finished formulation products cover dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments. The Company offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAL PHARMA LIMITED	+14.05%	22.88M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B